Details of the Drug

General Information of Drug (ID: DMEZGWP)

Drug Name

Zabedosertib

Synonyms

Zabedosertib; 1931994-81-8; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; Zabedosertib [INN]; BAY-1834845; N1GRK350ZM; BAY1834845; BAY 1834845; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; UNII-N1GRK350ZM; SCHEMBL17785221; GTPL11415; OQAMEEFUUFJZRS-UHFFFAOYSA-N; BDBM395297; EX-A5143; US10308634, Example 12; MFCD32900903; AKOS040755617; SB74225; MS-28697; SY323200; HY-139374; CS-0198831; D96922; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C20H21F3N4O4S
Canonical SMILES: CC(C)(C1=CC2=NN(C=C2C=C1NC(=O)C3=NC(=CC=C3)C(F)(F)F)CCS(=O)(=O)C)O
InChI: InChI=1S/C20H21F3N4O4S/c1-19(2,29)13-10-15-12(11-27(26-15)7-8-32(3,30)31)9-16(13)25-18(28)14-5-4-6-17(24-14)20(21,22)23/h4-6,9-11,29H,7-8H2,1-3H3,(H,25,28)
InChIKey: OQAMEEFUUFJZRS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 121364961
TTD ID: D5XVM6

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Renal carcinoma antigen NY-REN-64 (IRAK-4)	TTKFVXR	IRAK4_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05656911) A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis. U.S.National Institutes of Health.
2	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.